What Exactly is Mpox?
Mpox, formerly known as monkeypox, is a viral disease caused by the monkeypox virus, a member of the Orthopoxvirus genus. The virus primarily spreads through close contact with an infected person, contaminated materials, or infected animals. Mpox symptoms include fever, headaches, muscle aches, back pain, and a distinctive rash with pus-filled lesions. In severe cases, the virus can lead to complications and death, particularly in areas with limited healthcare resources.
Mpox Outbreak 2024: A Growing Global Health Emergency
The current mpox outbreak has its roots in the Democratic Republic of the Congo (DRC), where the virus has been endemic for decades. However, recent developments have raised significant concerns. A new viral strain, known as Clade 1b, has emerged and is spreading rapidly across central and eastern Africa, including Burundi, Kenya, Rwanda, and Uganda. This new strain, which appears to be more virulent and deadly, has led to over 15,000 suspected and confirmed cases and 537 deaths so far in 2024.
The declaration of the mpox outbreak as a global health emergency by WHO is the second in two years related to the virus. In July 2022, a different outbreak of mpox was also declared a PHEIC due to its rapid spread beyond Africa. This earlier outbreak was linked to a less severe strain of the virus and primarily affected men who have sex with men. Although that outbreak was eventually brought under control, the emergence of Clade 1b has reignited global concerns.
The Response to the Mpox Outbreak
WHO has called for an immediate and coordinated international response to the mpox outbreak. The organization has triggered the Emergency Use Listing (EUL) procedure for mpox vaccines, which will expedite vaccine access, especially for lower-income countries that have yet to approve the vaccines domestically. This is a critical step in curbing the spread of the virus, particularly in regions where healthcare infrastructure is already under strain.
Currently, two vaccines have been recommended by WHO for use against mpox: Bavarian Nordic’s Jynneos and LC16 by KM Biologics. These vaccines were utilized during the 2022 outbreak, but their availability in Africa remains limited. WHO has appealed for increased funding and support to ensure that these vaccines reach the affected regions promptly. The organization estimates an immediate funding requirement of $15 million to support surveillance, preparedness, and response activities.
Challenges in Controlling the Mpox Outbreak
Despite the urgent need for action, several challenges persist in controlling the mpox outbreak. Limited vaccine supply, logistical difficulties, and competing health emergencies are significant hurdles. For instance, while Africa CDC has secured $10.4 million in emergency funding and plans to acquire 3 million vaccine doses, the rollout of these vaccines may not begin until October 2024 at the earliest.
The DRC, which has been hardest hit by the outbreak, faces additional challenges. The country’s health infrastructure is already overwhelmed by conflicts and other disease outbreaks, such as measles and cholera. This makes the effective distribution of mpox vaccines and other medical resources even more critical.
The Importance of a Coordinated Global Response
The WHO’s declaration of the mpox outbreak as a global health emergency serves as a call to action for the international community. It emphasizes the need for a unified approach to stop the virus’s spread and prevent further loss of life. This includes increased surveillance, research into the new Clade 1b strain, and the equitable distribution of vaccines and other medical supplies.
In conclusion, the mpox outbreak represents a significant threat to global health, particularly in Africa. With the virus showing no signs of abating, immediate and coordinated efforts are essential to control its spread and mitigate its impact. The WHO, along with other international health organizations, is working tirelessly to address this crisis, but sustained global cooperation will be crucial in overcoming the challenges ahead.
